A Randomized Phase II Study of Concurrent Cisplatin-radiotherapy With or Without Neoadjuvant Chemotherapy Using Taxotere and Cisplatin in Advanced Nasopharyngeal Carcinoma (NPC)
Phase 2
18 Years
N/A
18 Years
N/A
Not Enrolling
Both
Nasopharyngeal Neoplasms
Both
Nasopharyngeal Neoplasms
Trial Information
A Randomized Phase II Study of Concurrent Cisplatin-radiotherapy With or Without Neoadjuvant Chemotherapy Using Taxotere and Cisplatin in Advanced Nasopharyngeal Carcinoma (NPC)
Inclusion Criteria:
- International Union against Cancer stages III and IV newly diagnosed NPC
Exclusion Criteria:
- Inadequate bone marrow reserve
- Inadequate renal function
- Other primary malignancy
- Evidence of distant metastases
The above information is not intended to contain all considerations relevant to a
patient's potential participation in a clinical trial.
Type of Study:
Interventional
Study Design:
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
Treatment response is evaluated by correlating findings on clinical examination, endoscopy, biopsy, Computed tomography or Magnetic resonance imaging as appropriate.
Outcome Time Frame:
From administration of drug to end of study
Safety Issue:
No
Principal Investigator
Iris Chan
Investigator Role:
Study Director
Investigator Affiliation:
Sanofi
Authority:
Hong Kong: Department of Health
Study ID:
XRP6976F_6002
NCT ID:
NCT00436293
Start Date:
December 2002
Completion Date:
March 2010
Related Keywords:
- Nasopharyngeal Neoplasms
- Neoplasms
- Carcinoma
- Nasopharyngeal Neoplasms
Name | Location |
|---|
